KYL peptide

KYL peptide, an antagonistic peptide, selectively targets EphA4 receptor (IC50:4.22 μM, Kd:1.3 μM). KYL peptide binds to the ligand-binding domain of EphA4, effectively alleviates Aβ-induced synaptic dysfunction and synaptic plasticity defects in AD mice. KYL peptide can promote nerve regeneration after injury and modulating immune responses[1][2][3].

CC(C)C[C@@H](C(O)=O)NC([C@H](CO)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H]1N(C([C@H](CC2=CNC3=C2C=CC=C3)NC([C@H](CC4=CC=C(O)C=C4)NC([C@H]5N(C([C@H](CC(C)C)NC([C@H](CC6=CC=C(O)C=C6)NC([C@H](CCCCN)N)=O)=O)=O)CCC5)=O)=O)=O)CCC1)=O)=O)=O)=O)=O

[1]Lamberto I, et, al. Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J. 2012 Jul 1;445(1):47-56.|[2]Fu AKY, et, al. Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease. Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9959-64.|[3]Wu B, et.al. HTS by NMR of combinatorial libraries: a fragment-based approach to ligand discovery. Chem Biol. 2013 Jan 24;20(1):19-33.